Revvity Q4 Earnings Call Highlights

Revvity (NYSE:RVTY) executives said the institution ended 2025 with results that exceeded interior expectations, helped by better-than-anticipated show successful diagnostics and improving trends successful parts of the beingness sciences portfolio. Management besides provided an archetypal 2026 outlook that assumes caller end-market stabilization continues but does not yet cook successful a broader recovery.

Chief Executive Officer Prahlad Singh said fourth-quarter revenue, integrated maturation and adjusted net per stock each came successful supra the company’s expectations, allowing Revvity to transcend its adjusted EPS guidance for the afloat year. Singh highlighted a fig of headwinds the institution navigated successful 2025, including changes successful NIH funding, evolving tariffs, pharma argumentation uncertainty, an extended U.S. authorities shutdown, overseas speech movements, and DRG-related measurement pressures successful China diagnostics.

→ Palantir Bulls Face a Reality Check Before Earnings

Chief Financial Officer Max Krakowiak reported fourth-quarter gross of $772 million, including 4% integrated growth and an approximate 2% foreign-exchange tailwind. Adjusted operating borderline was 29.7% successful the quarter, down 60 ground points year-over-year but successful enactment with institution expectations. Adjusted EPS was $1.70, which absorption said exceeded the precocious extremity of guidance.

For the afloat year, Revvity reported $2.86 billion successful revenue, including 3% integrated growth and a 1% FX tailwind. Full-year adjusted operating borderline was 27.1%, down 120 ground points year-over-year, with absorption citing unit from tariffs, FX, and little measurement leverage, partially offset by outgo containment initiatives. Full-year adjusted EPS was $5.06, up 3% year-over-year and supra the precocious extremity of the company’s archetypal guidance.

→ MarketBeat Week successful Review – 01/26 - 01/30

Management said diagnostics posted stronger-than-expected show successful the quarter. Krakowiak said diagnostics conception gross was $390 million, up 7% organically (10% reported). Life sciences conception gross was $382 million, level organically.

Within diagnostics, Krakowiak said:

• Immunodiagnostics grew precocious azygous digits organically successful the 4th and mid-single digits for the afloat year, with spot extracurricular China partially offset by double-digit declines successful China for the afloat twelvemonth owed to DRG-related measurement pressures.

• Reproductive Health grew mid-single digits organically successful the 4th and for the year. Management said newborn screening grew mid-single digits successful the 4th and precocious azygous digits for the afloat twelvemonth and cited contributions from enactment with Genomics England.